[Gliflozins-in future cardioprotective drugs?]

Abstract

Gliflozine (inhibitors of sodium-dependent glucose cotransporters, SGLT) are medications which were originally used in the treatment of diabetes mellitus and are assigned to the group of antidiabetics. Since November 2020 the SGLT2 inhibitor dapagliflozin has been approved for the treatment of heart failure (with reduced left ventricular function) for the first time, independent of the diabetes status. The substance empagliflozin has just received an approval for the treatment of heart failure with reduced ejection fraction from the European Medicines Agency (EMA). Therefore, different gliflozins are now available not only for the treatment of diabetes mellitus but also for the treatment of cardiac insufficiency. This article mediates fundamental knowledge on the gliflozins and provides an overview of the importance in the treatment of type 2 diabetes mellitus as well as cardioprotective and nephroprotective functions.

• Authors: Ursula Rauch-Kröhnert, Ulf Landmesser
• Journal: Der Internist (Internist (Berl)) Vol. 62 Issue 7 Pg. 786-795 (Jul 2021) ISSN: 1432-1289 [Electronic] Germany
• Vernacular Title: Gliflozine – in Zukunft Kardioprotektiva?
• PMID: 34164700 (Publication Type: Journal Article, Review)

Chemical References

• Hypoglycemic Agents
• Pharmaceutical Preparations
• Sodium-Glucose Transporter 2 Inhibitors

Topics

• Diabetes Mellitus, Type 2 (drug therapy)
• Heart Failure (drug therapy, prevention & control)
• Humans
• Hypoglycemic Agents
• Pharmaceutical Preparations
• Sodium-Glucose Transporter 2 Inhibitors (therapeutic use)